These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 25945652

  • 1. Modulation of insulin degrading enzyme activity and liver cell proliferation.
    Pivovarova O, von Loeffelholz C, Ilkavets I, Sticht C, Zhuk S, Murahovschi V, Lukowski S, Döcke S, Kriebel J, de las Heras Gala T, Malashicheva A, Kostareva A, Lock JF, Stockmann M, Grallert H, Gretz N, Dooley S, Pfeiffer AF, Rudovich N.
    Cell Cycle; 2015; 14(14):2293-300. PubMed ID: 25945652
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
    Kurauti MA, Costa-Júnior JM, Ferreira SM, Santos GJ, Sponton CHG, Carneiro EM, Telles GD, Chacon-Mikahil MPT, Cavaglieri CR, Rezende LF, Boschero AC.
    Sci Rep; 2017 Apr 21; 7():46750. PubMed ID: 28429777
    [Abstract] [Full Text] [Related]

  • 3. Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes.
    Rudovich N, Pivovarova O, Fisher E, Fischer-Rosinsky A, Spranger J, Möhlig M, Schulze MB, Boeing H, Pfeiffer AF.
    J Mol Med (Berl); 2009 Nov 21; 87(11):1145-51. PubMed ID: 19809796
    [Abstract] [Full Text] [Related]

  • 4. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Hastazeris K, Salmas M, Stefanaki S, Agnantis NJ.
    Urol Int; 2004 Nov 21; 73(1):65-73. PubMed ID: 15263796
    [Abstract] [Full Text] [Related]

  • 5. Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa.
    Kodani I, Shomori K, Osaki M, Kuratate I, Ryoke K, Ito H.
    Pathobiology; 2001 Nov 21; 69(3):150-8. PubMed ID: 11872961
    [Abstract] [Full Text] [Related]

  • 6. Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells.
    Pivovarova O, Gögebakan O, Pfeiffer AF, Rudovich N.
    Diabetologia; 2009 Aug 21; 52(8):1656-64. PubMed ID: 19396426
    [Abstract] [Full Text] [Related]

  • 7. Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice.
    Wei X, Ke B, Zhao Z, Ye X, Gao Z, Ye J.
    PLoS One; 2014 Aug 21; 9(4):e95399. PubMed ID: 24740421
    [Abstract] [Full Text] [Related]

  • 8. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
    Pivovarova O, Höhn A, Grune T, Pfeiffer AF, Rudovich N.
    Ann Med; 2016 Dec 21; 48(8):614-624. PubMed ID: 27320287
    [Abstract] [Full Text] [Related]

  • 9. Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting.
    Xu ZW, Wang FM, Gao MJ, Chen XY, Hu WL, Xu RC.
    Biol Pharm Bull; 2010 Dec 21; 33(5):743-51. PubMed ID: 20460749
    [Abstract] [Full Text] [Related]

  • 10. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
    Tang WJ.
    Trends Endocrinol Metab; 2016 Jan 21; 27(1):24-34. PubMed ID: 26651592
    [Abstract] [Full Text] [Related]

  • 11. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E.
    Int J Clin Pract; 2008 Nov 21; 62(11):1736-43. PubMed ID: 19143860
    [Abstract] [Full Text] [Related]

  • 12. Hyperinsulinemia caused by dexamethasone treatment is associated with reduced insulin clearance and lower hepatic activity of insulin-degrading enzyme.
    Protzek AO, Rezende LF, Costa-Júnior JM, Ferreira SM, Cappelli AP, de Paula FM, de Souza JC, Kurauti MA, Carneiro EM, Rafacho A, Boschero AC.
    J Steroid Biochem Mol Biol; 2016 Jan 21; 155(Pt A):1-8. PubMed ID: 26386462
    [Abstract] [Full Text] [Related]

  • 13. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.
    Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR.
    Nature; 2014 Jul 03; 511(7507):94-8. PubMed ID: 24847884
    [Abstract] [Full Text] [Related]

  • 14. FADD Phosphorylation Modulates Blood Glucose Levels by Decreasing the Expression of Insulin-Degrading Enzyme.
    Lin Y, Liu J, Chen J, Yao C, Yang Y, Wang J, Zhuang H, Hua ZC.
    Mol Cells; 2020 Apr 30; 43(4):373-383. PubMed ID: 32191993
    [Abstract] [Full Text] [Related]

  • 15. Correlations between insulin-degrading enzyme and metabolic markers in patients diagnosed with type 2 diabetes, Alzheimer's disease, and healthy controls: a comparative study.
    Kullenberg H, Rossen J, Johansson UB, Hagströmer M, Nyström T, Kumlin M, Svedberg MM.
    Endocrine; 2024 May 30; 84(2):450-458. PubMed ID: 37980298
    [Abstract] [Full Text] [Related]

  • 16. Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice.
    Merino B, Fernández-Díaz CM, Parrado-Fernández C, González-Casimiro CM, Postigo-Casado T, Lobatón CD, Leissring MA, Cózar-Castellano I, Perdomo G.
    Metabolism; 2020 Dec 30; 113():154352. PubMed ID: 32916153
    [Abstract] [Full Text] [Related]

  • 17. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
    Li H, Wu J, Zhu L, Sha L, Yang S, Wei J, Ji L, Tang X, Mao K, Cao L, Wei N, Xie W, Yang Z.
    Biosci Rep; 2018 Feb 28; 38(1):. PubMed ID: 29222348
    [Abstract] [Full Text] [Related]

  • 18. Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation.
    Merino B, Casanueva-Álvarez E, Quesada I, González-Casimiro CM, Fernández-Díaz CM, Postigo-Casado T, Leissring MA, Kaestner KH, Perdomo G, Cózar-Castellano I.
    Diabetologia; 2022 Aug 28; 65(8):1375-1389. PubMed ID: 35652923
    [Abstract] [Full Text] [Related]

  • 19. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
    Liu H, Chen F, Zhang L, Zhou Q, Gui S, Wang Y.
    Oncol Rep; 2016 Jul 28; 36(1):333-41. PubMed ID: 27177208
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features.
    Ioachim EE, Katsanos KH, Michael MC, Tsianos EV, Agnantis NJ.
    Int J Colorectal Dis; 2004 Jul 28; 19(4):325-33. PubMed ID: 15060836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.